Statins Tied to Lower Community-Acquired Staph Infection Risk
Decrease in risk of Staphylococcus aureus bacteremia is seen especially with long-term statin use
WEDNESDAY, Oct. 11, 2017 (HealthDay News) -- Statin use is associated with a decreased risk of community-acquired Staphylococcus aureus bacteremia (CA-SAB), particularly in long-term users, according to a study published in the October issue of Mayo Clinic Proceedings.
Jesper Smit, M.D., Ph.D., from Aalborg University Hospital in Denmark, and colleagues used population-based medical registries to identify 2,638 adults with first-time CA-SAB and 26,379 population controls matched for age, sex, and residence in northern Denmark (Jan. 1, 2000, through Dec. 31, 2011). Statin users were characterized as current users (new or long-term use), former users, and nonusers.
The researchers found that compared with nonusers, current statin users experienced markedly decreased risk of CA-SAB (adjusted odds ratio [OR], 0.73; 95 percent confidence interval, 0.63 to 0.84). The adjusted OR was 0.96 (95 percent confidence interval, 0.6 to 1.51) for new users, 0.71 (95 percent confidence interval, 0.62 to 0.82) for long-term users, and 1.12 (95 percent confidence interval, 0.94 to 1.32) for former users, all versus nonusers. Increasing intensity of statin use was associated with decreased CA-SAB risk compared with nonusers (adjusted OR, 0.84 [95 percent confidence interval, 0.68 to 1.04] for current users with daily dosages <20 mg/day; 0.71 [95 percent confidence interval, 0.58 to 0.87] for 20 to 39 mg/day, and 0.63 [95 percent confidence interval, 0.49 to 0.81] for 40 mg/day or more). However, there were no differences in CA-SAB risk with increases in duration of statin use.
"Our results warrant confirmation in other settings and study designs, and the biological mechanisms by which statin treatment may protect against CA-SAB should be explored further," conclude the authors.
Several authors disclosed ties to the pharmaceutical industry.